Education
About Us
Working with TipRanks
Follow Us
ASKA Pharmaceutical Holdings Co., Ltd. (JP:4886)
:4886
RESEARCH TOOLSreports
Total Valuation
ASKA Pharmaceutical Holdings Co., Ltd. has a market cap or net worth of ¥60.01B. The enterprise value is ―.
Market Cap¥60.01B
Enterprise Value―
Share Statistics
ASKA Pharmaceutical Holdings Co., Ltd. has 28,763,199 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,763,199
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ASKA Pharmaceutical Holdings Co., Ltd.’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 6.93%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)6.93%
Return on Capital Employed (ROCE)0.10
Revenue Per Employee82.47M
Profits Per Employee9.90M
Employee Count762
Asset Turnover0.69
Inventory Turnover1.58
Valuation Ratios
The current PE Ratio of ASKA Pharmaceutical Holdings Co., Ltd. is 8.11. ASKA Pharmaceutical Holdings Co., Ltd.’s PEG ratio is -0.96.
PE Ratio8.11
PS Ratio0.00
PB Ratio1.01
Price to Fair Value0.99
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio-0.96
Income Statement
In the last 12 months, ASKA Pharmaceutical Holdings Co., Ltd. had revenue of 62.84B and earned 7.54B in profits. Earnings per share was 266.49.
Revenue62.84B
Gross Profit30.66B
Operating Income6.50B
Pretax Income9.86B
Net Income7.54B
EBITDA12.57B
Earnings Per Share (EPS)266.49
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
ASKA Pharmaceutical Holdings Co., Ltd. pays an annual dividend of ¥25, resulting in a dividend yield of 2.4%
Dividend Per Share¥25
Dividend Yield2.4%
Payout Ratio13.89%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.60
52-Week Price Change6.21%
50-Day Moving Average2.27K
200-Day Moving Average2.13K
Relative Strength Index (RSI)51.18
Average Volume (3m)46.28K
Important Dates
ASKA Pharmaceutical Holdings Co., Ltd. upcoming earnings date is Aug 11, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 11, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
ASKA Pharmaceutical Holdings Co., Ltd. as a current ratio of 2.34, with Debt / Equity ratio of 11.39%
Current Ratio2.34
Quick Ratio1.49
Debt to Market Cap0.16
Net Debt to EBITDA-0.34
Interest Coverage Ratio162.50
Taxes
In the past 12 months, ASKA Pharmaceutical Holdings Co., Ltd. has paid 2.32B in taxes.
Income Tax2.32B
Effective Tax Rate0.23
Enterprise Valuation
ASKA Pharmaceutical Holdings Co., Ltd. EV to EBITDA ratio is 4.53, with an EV/FCF ratio of 1.72K.
EV to Sales0.91
EV to EBITDA4.53
EV to Free Cash Flow1.72K
EV to Operating Cash Flow38.29
Balance Sheet
ASKA Pharmaceutical Holdings Co., Ltd. has ¥10.17B in cash and marketable securities with ¥7.42B in debt, giving a net cash position of -¥2.74B billion.
Cash & Marketable Securities¥10.17B
Total Debt¥7.42B
Net Cash-¥2.74B
Net Cash Per Share-¥95.30
Tangible Book Value Per Share¥2.09K
Margins
Gross margin is 49.25%, with operating margin of 10.34%, and net profit margin of 12.01%.
Gross Margin49.25%
Operating Margin10.34%
Pretax Margin15.69%
Net Profit Margin12.01%
EBITDA Margin20.00%
EBIT Margin15.76%
Analyst Forecast
The average price target for ASKA Pharmaceutical Holdings Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast3.09%
EPS Growth Forecast-20.48%